End-Stage Kidney Disease Treatment Market
End-Stage Kidney Disease Treatment Market Size, Share & Trends by Diagnosis (Dialysis and Medication and Kidney Transplantation) and by Application (Clinics and Hospitals) Forecast (2022-2028) Update Available - Forecast 2024-2030
The global end-stage kidney disease treatment market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Chronic kidney disease is also referred to as kidney failure, which involves a gradual loss of kidney function. The rise in the prevalence of chronic kidney diseases is anticipated to drive the global end-stage kidney disease treatment market. For instance, in 2021, according to National Center for Biotechnology Information (NCBI), Chronic kidney disease has been recognized as the leading public health problem globally. Further, NCBI estimated that the prevalence of chronic kidney disease (CKD) is 13.4 % globally. Moreoevr, patients with end-stage kidney disease (ESKD) in the need of kidney replacement therapy is estimated between 4.9 million to 7 million in 2021. Thus, the rise in patients with kidney diseases is one of the driving factors in boosting the market during the forecast period.
Impact of COVID-19 on Global End-Stage Kidney Disease Treatment Market
The COVID-19 pandemic has resulted in a decline in the growth of the end-stage kidney disease treatment market. The diagnosis of various kidney-related diseases has been postponed during the COVID-19 pandemic as non-urgent procedures were given the least preference by the authorities. Moreover, medical services were remained closed due to lockdowns and restrictions that resulted as a major factor for the decline in the growth of the end-stage kidney disease treatment market. Moreover, the unwillingness of people to visit healthcare facilities due to fear of getting infected and social distancing resulted in a low number of hospital visits which also adds to the declining factor.
Segmental Outlook
The global end-stage kidney disease treatment market is segmented based on the type of treatment and application. Based on the type of treatment, the market is sub-segmented into dialysis and medication, and kidney transplantation. Based on the application, the market is further segmented into clinics and hospitals. Among these, the hospital segment is anticipated to hold a considerable share in the market owing to the surge in demand for end-stage kidney disease treatment due to rise in the number of patients suffering from kidney diseases.
Global End-Stage Kidney Disease Treatment Market Share by Type of Treatment 2021 (%)
The Kidney Transplantation Segment is Anticipated to Hold a Prominent Share in the Global End-Stage Kidney Disease Treatment.
The kidney transplantation segment is anticipated to hold a prominent share in the market owing to the rise in the prevalence of chronic kidney diseases which is further leading to a rise in the number of kidney transplantations. For instance, in 2021, according to the center for disease control and prevention (CDC), 37 million adults in the US adults are estimated to have chronic kidney disease. Further, chronic kidney diseases are common in 38% of people aged 65 years or above. Also, according to the US Renal Data system, the annual data report, in 2020, estimated that 786,000 people in the US suffered from end-stage kidney disease (ESDK) wherein 29 % of people underwent a kidney transplant. Thus, these factors are expected to drive the kidney transplantation segment, further boosting the growth of the global end-stage kidney disease treatment market.
Regional Outlook
The global end-stage kidney disease treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among these, the Asia-pacific region is expected to hold a considerable share in the market during the forecast period owing to a rise in government initiatives for dialysis treatments.
Global End-Stage Kidney Disease Treatment Market, by Region 2022-2028
The North American Region is Estimated to Hold Major Share in Global End-Stage Kidney Disease Treatment Market.
North America region is anticipated to hold a prominent share in market owing to rise in the awareness about kidney related diseases. For instance , the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) promotes an Kidney Disease Program which is an integrated health care system clinical care based on experiences of HIS’. The NIDDK has also developed new clinical tools and educational programs that improve the care of the people with kidney diseases in primary care settings. Furthermore , NIDDK collaborated with government , nonprofit and health care organizations to raise awaress and educate people about the risk of kidney diseases and ways to manage kidney diseases. Thus , the rise in the awareness among the kidney related diseases is anticipated to drive the demand for global end stage kidney disease treatment market in the region during the forecast period .
Market players Outlook
The major companies serving the global knee implant market are BLR Bio LLC, Novartis AG, Prolong Pharmaceuticals LLC, VESSL Therapeutics Ltd, CTI BioPharma Corp, and more. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2021, Baxter International has launched Sharesource Analytics 1.0 premium module, which is the next generation for home-based peritoneal dialysis patients. The sharesource remote patient management platform provides health care professionals with a digital dashboard containing the trend data of home dialysis patients' treatment.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global end-stage kidney disease treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global End-Stage Kidney Disease Treatment Market
• Recovery Scenario of Global End-Stage Kidney Disease Treatment Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Arcturus Therapeutics Holdings Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. BLR Bio LLC.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. CTI Biopharma Corp.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Prolong Pharmaceuticals LLC.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Novartis AG
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global End-Stage Kidney Disease Treatment Market by Type of Treatment
4.1.1. Medication and Kidney Transplantation
4.1.2. Dialysis
4.2. Global End-Stage Kidney Disease Treatment Market by Application
4.2.1. Clinics
4.2.2. Hospitals
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Amgen Inc.
6.2. AmbioPharm, Inc.
6.3. AstraZeneca plc.
6.4. Daiichi Sankyo Co.
6.5. Dr.Reddys Laboratories, Ltd.
6.6. FibroGen Inc.
6.7. Ionis Pharmaceuticals, Inc.
6.8. Johnson & Johnson Services, Inc.
6.9. Kerxy Biopharmaceuticals Inc.
6.10. Kissei Pharmaceuticals Co.Ltd
6.11. SANOFI
6.12. Takeda Pharmacuetical Co ,Ltd.
6.13. Teva Pharmaceutical Industries
1. GLOBAL END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF TREATMENT, 2021-2028 ($ MILLION)
2. GLOBAL MEDICATION AND KIDNEY TRANSPLANTATION FOR END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL DIALYSIS FOR END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
5. GLOBAL CLINICS IN END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL HOSPITALS IN END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
8. NORTH AMERICAN END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
9. NORTH AMERICAN END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF TREATMENT, 2021-2028 ($ MILLION)
10. NORTH AMERICAN END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
11. EUROPEAN END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
12. EUROPEAN END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF TREATMENT, 2021-2028 ($ MILLION)
13. EUROPEAN END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
14. ASIA-PACIFIC END STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
15. ASIA-PACIFIC END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF TREATMENT 2021-2028 ($ MILLION)
16. ASIA-PACIFIC END STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
17. REST OF THE WORLD END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. REST OF THE WORLD END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF TREATMENT, 2021-2028 ($ MILLION)
19. REST OF THE WORLD END-STAGE KIDNEY DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL END-STAGE KIDNEY DISEASE TREATMENT MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL END-STAGE KIDNEY DISEASE TREATMENT MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL END-STAGE KIDNEY DISEASE TREATMENT MARKET, 2021-2028 (%)
4. GLOBAL END-STAGE KIDNEY DISEASE TREATMENT MARKET SHARE BY TYPE OF TREATMENT, 2021VS 2028 (%)
5. GLOBAL MEDICATION AND KIDNEY TRANSPLANTATION FOR END-STAGE KIDNEY DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
6. GLOBAL DIALYSIS FOR END-STAGE KIDNEY DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
7. GLOBAL END-STAGE KIDNEY DISEASE TREATMENT MARKET SHARE BY APPLICATION, 2021VS 2028 (%)
8. GLOBAL CLINICS IN END-STAGE KIDNEY DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
9. GLOBAL HOSPITALS IN END-STAGE KIDNEY DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
10. US END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
11. CANADA END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
12. UK END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
13. FRANCE END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
14. GERMANY END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
15. ITALY END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
16. SPAIN END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
17. REST OF EUROPE END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
18. INDIA END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
19. CHINA END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
20. JAPAN END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
21. SOUTH KOREA END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF ASIA-PACIFIC END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD END-STAGE KIDNEY DISEASE TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)
